A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
This clinical trial is studying an experimental medicine called LY4584180 in adults with blood cancers called lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma. It is aimed at patients whose cancer has come back or has not responded to standard therapies. Because this is a Phase 1 study, it is the first time this medicine is being given to humans. The main goal is not yet to prove how well the drug works, but to check its safety, discover possible side effects, and find the most suitable dose for future studies. Participants will receive the study drug under close medical observation. Doctors will perform regular health checks, blood tests, and scans to monitor safety and see how the body responds. Taking part is completely voluntary and does not replace open conversations with your regular cancer care team.
At a glance
What is this study about?
This clinical trial is exploring a brand-new medicine called LY4584180. It is designed for adults who have specific types of blood cancer known as non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma. These cancers affect the lymphatic system, which is part of the body's immune defence. For many people, existing treatments work well, but sometimes the cancer returns or stops responding to standard therapies. When this happens, new treatment options are urgently needed.
This study is a Phase 1 clinical trial, which means it is the very first time LY4584180 is being tested in humans. In early trials like this, researchers start with small amounts of the medicine and gradually increase the dose in small groups of volunteers. This careful approach helps the research team monitor safety closely, see how the drug moves through the body, and determine the safest and most effective dose for future testing.
Trials of this kind are vital for developing the next generation of cancer treatments. While researchers hope the medicine will help control the cancer, the primary focus is learning how it behaves in real patients. The information gathered here will shape how this medicine is studied in larger trials in the future.
Key takeaways
- Testing a new medicine called LY4584180 for adults with treated blood cancers.
- First time the drug is being given to humans (Phase 1 trial).
- Aimed at people aged 18 and older with certain types of lymphoma.
- Main goals are checking safety, managing side effects, and finding the right dose.
- Participation is voluntary, and you can withdraw at any time.
Who may be eligible?
To take part in this trial, you must be 18 years of age or older and have a confirmed diagnosis of a specific blood cancer, such as diffuse large B-cell lymphoma or follicular lymphoma. This study is aimed at people whose cancer has already been treated with standard cancer therapies, but has either returned or not fully responded.
You will need to be well enough to carry out everyday activities, and your key organs, such as your heart, liver, and kidneys, must be working reasonably well to ensure you can safely receive the treatment.
You might not be able to join if you have certain other active medical conditions, severe infections, or if you are pregnant or breastfeeding. The trial team will carry out a thorough set of checks and discuss your complete medical history to make sure taking part is as safe as possible for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with a blood cancer such as non-Hodgkin lymphoma.
- I have already received standard cancer treatment, but my cancer has returned or progressed.
- I am well enough to look after myself and travel to hospital appointments.
- I am willing to undergo regular blood tests, scans, and clinic visits.
What does participation involve?
Taking part in this study means visiting a specialist hospital clinic regularly. At the beginning, the team will run tests such as blood samples, scans, and physical exams to ensure the trial is right for you. You will then receive the experimental medicine under close medical supervision. Because this is an early-stage trial, you will need frequent hospital visits so the doctors can check your vital signs, collect blood to measure drug levels, and watch closely for any side effects. You will also have periodic scans to see how your cancer is responding. The study usually lasts several months, but you can continue as long as the treatment helps you and does not cause troublesome side effects. After finishing treatment, the team will follow up on your health for a set period.
Potential risks and benefits
Locations (5)
- —UnverifiedSpain
- —UnverifiedPoland
- —UnverifiedItaly
- —UnverifiedFrance
- —UnverifiedGermany
Common questions
What does a Phase 1 trial mean?
A Phase 1 trial is the earliest stage of testing in humans. Its main purpose is to check safety, find the right dose, and see how the human body handles the new medicine.
Will I definitely receive the study medicine?
Yes. In Phase 1 studies of this type, all participants generally receive the experimental drug; there is usually no dummy drug (placebo).
Do I have to pay for the trial treatment?
No, clinical trial medicines and study-related tests are provided free of charge, and some travel costs may be reimbursed.
Can I leave the trial if I change my mind?
Yes, you are free to leave the trial at any point. Your decision will never harm your relationship with your healthcare team or your standard NHS treatment.
Will this drug cure my blood cancer?
It is too early to know if this medicine can cure cancer. Early trials are designed to test safety rather than guarantee a cure.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.